Onco360 named limited-distribution pharmacy network participant for new Pfizer breast cancer treatment

LOUISVILLE, Ky. — Onco360 on Monday announced that it has been selected by Pfizer as a limited-distribution pharmacy network participant for Ibrance (palbociclib), Pfizer’s recently approved product for certain breast cancers. The addition of this medication marks another key product win for Onco360, which continues to grow its portfolio of limited distribution products.

 

“In the last 12 months, Onco360 has been selected as a network pharmacy provider for 10 limited distribution products, further enhancing our portfolio and reflecting the success of our oncology pharmacy model,” stated Paul Jardina, president and CEO of Onco360. “We are pleased to expand our relationship with Pfizer, and we are excited about the resonance and recognition the Onco360 oncology pharmacy model is garnering in the marketplace. As part of our commitment to cancer patients and their healthcare teams, Onco360 will continue to provide the most comprehensive pharmacy and clinical support services possible.”

 

On Feb. 3, 2015, the U.S. Food and Drug Administration approved Ibrance as a combination therapy for the treatment of certain types of breast cancer. 

 

Ibrance is a kinase inhibitor indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease1.